- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Bal Pharma launches Favipiravir under brand name BALflu
BALflu has the efficacy to clear the virus faster by 28.7% and is marketed at a very affordable price of Rs. 85 per tablet, said Managing Director Shailesh Siroya.
Bengaluru: Drugmaker, Bal Pharma Ltd, has recently announced the launch of Favipiravir formulation into Indian market, under the brand name BALflu.
Favipiravir is an emerging anti viral drug used for patients with mild to moderate Covid-19 infection. This formulation is available in tablets form with 400 mg strength. Favipiravir inhibits and terminates viral protein synthesis and induces lethal metagenesis of influenza virus.
BALflu (Favipiravir) is a broad spectrum formulation also used in the treatment of 53 types of Influenza virus including seasonal strains such as Ebola virus, arenavirus, bunyavirus, flovirus, west nile virus , food & mouth disease virus and lassa virus.
BALflu (Favipiravir) is approved by Drug Controller General of India (DCGI) for emergency use for the treatment of COVID-19 with an recommended dosage of 1800 mg on the first day followed by 800 mg from day 2 to 14.
Read also: Brinton Pharma to ramp up Favipiravir production
Mr.Shailesh Siroya , Managing Director of the Company speaking at the launch of the product has said that the BALflu has the efficacy to clear the virus faster by 28.7% and is marketed at a very affordable price of Rs.85 per tablet, so as to enable the needy patients to access this drug on time.
BALflu (Favipiravir) is made available across all the major markets in India as a prescription drug.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751